With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Alume Biosciences is pleased to announce the appointment of Rick Gonzalez as Chief Commercial Officer. With over three ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...

Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1," the size of the global biotechnology industry ...

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease ...

Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for the company’s Genzyme unit. A pharmaceutical physician with experience in R&D, global medical affairs ...

The Catawba Valley Leadership Foundation (CVLF) has announced the appointment of a new executive director. She is Dawn Hayden ...

Unrelated to this work, NDS is a consultant for Biogen, Merck, Novartis, Sanofi-Genzyme, Roche, and Teva and is on the speakers’ bureaus of Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. He ...